Silence Therapeutics PLC Director/PDMR Shareholding (7226O)
October 03 2019 - 9:40AM
UK Regulatory
TIDMSLN
RNS Number : 7226O
Silence Therapeutics PLC
03 October 2019
Director/PDMR Shareholding
October 3, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the
Company") a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases, today
announces that on October 2(nd) 3,171 Shares were purchased by
Alistair Gray, Non-Executive Director of the Company, at GBP1.89
per share.
Following this purchase, Alistair Gray is interested in 7,019
ordinary shares (0.01%) of the issued share capital of the Company
and will be interested in 8,645 ordinary shares (0.01%) of the
issued share capital of the Company following the admission of the
new shares on October 7(th) pursuant to his exercise of Conditional
Share Awards announced on October 1(st) .
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Alistair Gray
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP1.89 3,171
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 3,171 Ordinary Shares
- Price GBP5,993.19
--------------------------- --------------------------------------------
e) Date of the transaction 02 October 2019
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Dr David Horn Solomon, Chief Executive Officer 6900
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its
proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional
level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's
proprietary RNA chemistries and
delivery systems are designed to improve the stability of our
molecules and enhance effective delivery
to target cells, providing a powerful modular technology well
suited to tackle life-threatening diseases.
For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBSBDGRXGBGCX
(END) Dow Jones Newswires
October 03, 2019 10:40 ET (14:40 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024